325 related articles for article (PubMed ID: 37766573)
1. Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease.
Ogata H; Sugawara H; Yamamoto M; Ito H
J Atheroscler Thromb; 2024 Jan; 31(1):1-14. PubMed ID: 37766573
[TBL] [Abstract][Full Text] [Related]
2. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
3. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
Yamada S; Nakano T
J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
[TBL] [Abstract][Full Text] [Related]
4. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
[TBL] [Abstract][Full Text] [Related]
7. Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism.
Lau WL; Ix JH
Semin Nephrol; 2013 Mar; 33(2):93-105. PubMed ID: 23465497
[TBL] [Abstract][Full Text] [Related]
8. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
Kaur R; Singh R
Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
[TBL] [Abstract][Full Text] [Related]
10. Vascular calcification in chronic kidney disease.
Jono S; Shioi A; Ikari Y; Nishizawa Y
J Bone Miner Metab; 2006; 24(2):176-81. PubMed ID: 16502129
[TBL] [Abstract][Full Text] [Related]
11. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
12. Mineral metabolism and cardiovascular disease in CKD.
Fujii H; Joki N
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria and vascular calcification in chronic kidney disease: Lessons learned from the past to improve future therapy.
Pongsuwan K; Kusirisin P; Narongkiattikhun P; Chattipakorn SC; Chattipakorn N
J Cell Physiol; 2022 Dec; 237(12):4369-4396. PubMed ID: 36183389
[TBL] [Abstract][Full Text] [Related]
14. Serum Calcification Propensity and Clinical Events in CKD.
Bundy JD; Cai X; Mehta RC; Scialla JJ; de Boer IH; Hsu CY; Go AS; Dobre MA; Chen J; Rao PS; Leonard MB; Lash JP; Block GA; Townsend RR; Feldman HI; Smith ER; Pasch A; Isakova T;
Clin J Am Soc Nephrol; 2019 Nov; 14(11):1562-1571. PubMed ID: 31658949
[TBL] [Abstract][Full Text] [Related]
15. Smooth Muscle-Selective Nuclear Factor-κB Inhibition Reduces Phosphate-Induced Arterial Medial Calcification in Mice With Chronic Kidney Disease.
Yoshida T; Yamashita M; Horimai C; Hayashi M
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29146611
[TBL] [Abstract][Full Text] [Related]
16. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
Hruska KA; Mathew S
Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
[TBL] [Abstract][Full Text] [Related]
17. The mechanisms of hyperphosphatemia-induced vascular calcification.
Cozzolino M; Gallieni M; Brancaccio D
Int J Artif Organs; 2008 Dec; 31(12):1002-3. PubMed ID: 19115191
[TBL] [Abstract][Full Text] [Related]
18. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
19. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
[TBL] [Abstract][Full Text] [Related]
20. Niacin and Chronic Kidney Disease.
Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
